Bioniche E. coli O157:H7 Vaccine Discussed at 4th International Conference on Vaccines for Enteric Diseases

    - results of challenge and field studies with vaccine presented -

    BELLEVILLE, ON, April 30 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC),
a research-based, technology-driven Canadian biopharmaceutical company,
presented data at the 4th International Conference on Vaccines for Enteric
Diseases, held last week in Lisbon, Portugal. Dr. Dragan Rogan, Vice-President
of Animal Health Research & Development with Bioniche Life Sciences Inc.
presented a paper entitled, "Vaccination reduces shedding and colonization of
E. coli O157:H7 in cattle", which was co-authored by Dr. Andrew Potter,
Vaccine and Infectious Disease Organization (VIDO) - University of
Saskatchewan, Dr. David Smith, University of Nebraska-Lincoln, and Colin
Strauss, Bioniche Life Sciences Inc.
    In his presentation, Dr. Rogan noted that enterohaemorrhagic Escherichia
coli O157:H7 (EHEC) is an important pathogen of humans for which cattle are an
important reservoir and the main source of illness, either through direct
contact such as petting zoos or consumption of contaminated meat products; or
indirectly, through consumption of fruits and vegetables which have been
irrigated with contaminated water.
    Dr. Rogan suggested that the prevalence of E. coli O157:H7 in cattle
herds varies substantially, but is highest during the summer months (as high
as 80%), which can lead to as many as half of the carcasses becoming
contaminated in the slaughter plant. This increased summer prevalence
coincides with increased rates of ground beef contamination and the increased
incidence of human infections reported during the summer.
    "Pre-slaughter interventions represent a promising means of reducing the
risk of human infection," said Dr. Rogan. "Simulation models have demonstrated
that reducing the number of bacteria in pre-slaughter cattle would be the best
way to reduce EHEC incidence of disease in humans. To that end, several
approaches have been evaluated at the feedlot level such as changes to animal
husbandry practices, modification of feed rations, feeding of probiotics,
antibiotics, and bacteriophages. To date however, vaccination appears to be
the single most effective method of reducing E. coli O157:H7 at the feedlot
    Controlled challenge studies demonstrated that vaccination with
Bioniche's E. coli O157:H7 Type III Secreted Protein (TTSP) vaccine (3 doses,
3 weeks apart) resulted in a 36.5% reduction in the number of days the
bacterium was shed in the feces (P(less than)0.05), and a 2.28 log(10)
reduction in the number of bacteria being shed in the feces; resulting in a
vaccine efficacy of more than 99%.
    The efficacy of Bioniche's vaccine was also evaluated under feedlot
(field) conditions where cattle are naturally exposed to high levels of
E. coli O157:H7 during the summer months. The most recent of these for which
published data is available were conducted in 2004. 144 cows were vaccinated,
and these animals were less likely to be colonized by E. coli O157:H7 in the
mucosa of the terminal rectum as compared to the placebo group. A large-scale
feedlot study was also conducted in 2004 across nineteen commercial feedlots
(n=20,556 vaccinates) to evaluate the efficacy of only 2 vaccinations, upon
entry and again at re-implantation. This study demonstrated that, as compared
to unvaccinated cattle on a pen basis, vaccinated cattle had a 75% lower
probability for being colonized by E. coli O157:H7 and were less likely to
test ROPES-positive (ropes were hung over the feed bunks as a means of
assessing environmental contamination by means of cattle saliva), indicating
that the vaccine reduced environment exposure of cattle to E. coli O157:H7.
    While it is clear that the reduction of E. coli O157:H7 in the feedlot
and the environment is best achieved by reducing the shedding of the organism
in the feces, there are some researchers who believe that E. coli O157:H7
contamination of abattoir facilities comes predominately from the hides as
opposed to the intestinal waste. In order to evaluate the effect of Bioniche's
vaccine on hide contamination a feedlot study was conducted in 2005 (n=168
vaccinates) in which it was demonstrated that the hides of vaccinated animals
were 58% less likely to be contaminated than animals received the placebo
    "We have seen consistent results in both field and challenge studies
which demonstrate that the Bioniche E. coli O157:H7 vaccine is effective in
reducing the amount of this bacteria shed into the environment," added
Dr. Rogan.
    The Company is scaling up production of the vaccine at its Belleville,
Ontario, Canada facility in anticipation of commercial launch of the vaccine
in Canada in July of this year. The Company received authorization from the
Canadian Food Inspection Agency in December, 2006 to make the vaccine
available to veterinarians under a Permit to Release Veterinary Biologics. The
Company is pursuing full registration in both Canada and the U.S.

    About Bioniche Life Sciences Inc.

    Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
185 skilled personnel and has three operating business units: Human Health,
Animal Health, and Food Safety. The Company's primary goal is to develop
proprietary cancer therapies supported by revenues from marketed products in
human and animal health. For more information, please visit

    Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.
    %SEDAR: 00013159EF

For further information:

For further information: Jennifer Shea, Corporate Communications &
Investor Relations Manager, Bioniche Life Sciences Inc., Telephone: (613)
966-8058 ext. 1250, Cell: (613) 391-2097,

Organization Profile

Telesta Therapeutics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890